Our Tests Clinical Science Resources About Us For Patients For Investors Contact Us FOR INVESTORS News, events, and reports. Investor Presentations Recent Healthcare Conferences VIEW OUR PRESENTATIONS Scientific Evidence MammaPrint and BluePrint Utility VIEW OUR LANDMARK TRIALS Reach out to our investor relations department. CONTACT US Recent Events & News Healthcare Conferences Agendia’s leadership team presents at healthcare conferences globally to share updates on the company and our vision for how we fit into the breast cancer treatment space VIEW PRESENTATIONS HERE MINDACT Update Long term follow up data for the EORTC’s landmark MINDACT trial were presented at major conferences in 2020 and confirm MammaPrint’s utility for women with breast cancer VIEW DATA HERE NBRST Update Five-year follow up data for Agendia’s prospective NBRST trial were presented at SABCS 2020 and confirm the utility of our tests for pre-operative treatment planning VIEW DATA HERE SABCS 2020 Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming […] VIEW MORE INFORMATION Latest News Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […] READ THE ARTICLE Patient News Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer. VIEW THE DOCUMENTARY Investor News Agendia’s MammaPrint Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial June 7th, 2021 MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy MammaPrint testing for endocrine management decisions will be available in the US and the rest of the world as early as Q3 2021 June 07, 2021 05:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced positive results from an analysis using its 70-gene MammaPrint® assay on samples from the NSABP B-42 trial. These results were reported as an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, titled “Utility of the 70-gene MammaPrint assay for prediction of benefit Read More Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers June 5th, 2021 Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk June 05, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation. The presentation will detail an additional risk threshold previously established within the MammaPrint Low Risk category, identifying patients with an Ultra Low Risk of distant recurrence, essentially meaning the patient’s tumor is very unlikely to recur or metastasize over at Read More Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations June 4th, 2021 Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate abstract shows MammaPrint reclassified 57% of Oncotype results in tumors from African American patients as higher risk Data presented highlights need for genomic information that is representative of and effective for diverse patient groups June 04, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data from the national FLEX registry that identify differences Read More ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes June 4th, 2021 Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate abstract shows MammaPrint reclassified 57% of Oncotype results in tumors from African American patients as higher risk Data presented highlights need for genomic information that is representative of and effective for diverse patient groups June 04, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data from the national FLEX registry that identify differences Read More Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer April 28th, 2021 Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe Research Triangle Park, NC, USA, Cambridge, UK, Irvine, Calif., and Amsterdam – 28 April 2021 – Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer. Under the terms of the agreement, Agendia will gain co-exclusive rights to distribute Inivata’s RaDaR® liquid biopsy assay for the detection of Minimal Residual Disease (MRD) and early detection of relapse in patients with breast cancer in North America and Europe, with the option of extending territories over time. It is expected that the RaDaR assay will be reimbursed Read More Landmark Long-Term Data from EORTC’s MINDACT Study Published in The Lancet Oncology March 12th, 2021 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 12, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial designed to further confirm the clinical utility of MammaPrint risk scoring when determining a breast cancer patient’s need for chemotherapy, was published in The Lancet Oncology, and can be viewed online here. As previously reported at the ASCO conference in May 2020, the European Breast Cancer Conference in October 2020, and highlighted in an oral presentation at SABCS in December 2020, the data published in The Lancet Oncology confirm MINDACT as a positive de-escalation study, and show that nearly half of women who would have Read More 1 2 Next Quick Links Our Tests Resources Landmark Trials Order A Test For Patients Legal Privacy Policy Legal & Compliance Terms & Conditions Licenses & Accreditations Contact For the US, Puerto Rico, Canada and South America Agendia Inc. USA, 22 Morgan, Irvine, CA 92618 (888) 321-2732 customercare@agendia.com For outside the Americas Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands +31 (0)20 462 1510 customerservice@agendia.com © 2021 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc. This website uses cookies to provide you with the best possible experience. By using this website, you agree to our terms and conditions and privacy policy. ACCEPT